Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.55 |
| ▸ | MMP3 | P08254 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17899872 | 0.84 | SLC22A12 (0.65) | SLC22A12MMP3CA1CA2CYP19A1 | |
| SCHEMBL17899858 | 0.83 | SLC22A12 (0.74) | SLC22A12MMP3CA1CA2GPR119 | |
| SCHEMBL19453071 | 0.80 | SLC22A12 (0.46) | SLC22A12MMP3CA1CA2GPR119 | |
| SCHEMBL28385860 | 0.80 | SLC22A12 (0.46) | SLC22A12MMP3CA1CA2GPR119 | |
| SCHEMBL19435501 | 0.80 | SLC22A12 (0.55) | SLC22A12MMP3CA1CA2GPR119 | |
| SCHEMBL28387537 | 0.76 | SLC22A12 (0.51) | SLC22A12MMP3CA1CA2GPR119 | |
| SCHEMBL17899876 | 0.75 | SLC22A12 (0.67) | SLC22A12 | |
| SCHEMBL29441758 | 0.75 | SLC22A12 (0.67) | SLC22A12 | |
| SCHEMBL23129626 | 0.74 | SLC22A12 (0.57) | SLC22A12MMP3CA1CA2CYP19A1 | |
| SCHEMBL28387514 | 0.71 | SLC22A12 (0.67) | SLC22A12MMP3CA1CA2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241822-B1 | URAT1 INHIBITOR | NIPPON CHEMIPHAR CO (JP) | 2021-03-24 | — | — | EP | claimed |
| CN-107108478-B | URAT1 inhibitors | 日本化学药品株式会社 | 2020-04-24 | — | — | CN | disclosed |
| US-20170290795-A1 | URAT1 INHIBITOR | J-PHARMA CO., LTD. (JP) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290795-A1 | URAT1 INHIBITOR | SLC10A1, XDH, URB2 | SLC22A12 512/4885MMP3 2867/4885CA1 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.